PC3 is a cell line characteristic of prostatic small cell carcinoma

Prostate - Tập 71 Số 15 - Trang 1668-1679 - 2011
Sheng Tai1,2, Ying Sun1, Zhen Li1, Hong Zhang1,3, William Oh4, Chaozhao Liang5,2,6, Jiaoti Huang5,1,6
1Department of Pathology, Jonsson Comprehensive Cancer Center and Broad Center for Regenerative Medicine and Stem Cell Biology, David Geffen School of Medicine at UCLA, Los Angeles, California
2Department of Urology, the Geriatrics Research Institute, the First Affiliated Hospital of Anhui Medical University, Anhui, China
3Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Anhui, China
4Department of Medicine and Urology, the Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York
5Chao-Zhao Liang, Department of Urology, the Geriatric Research Institute, the First Affiliated Hospital of Anhui Medical University, 218 Jixi Ave., Hefei, Anhui 230022, China.
6Jiaoti Huang, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave., 13-229 CHS, Los Angeles, CA 90095-1732.

Tóm tắt

AbstractBACKGROUNDThe majority of the prostatic cancers are adenocarcinomas characterized by glandular formation and the expression of luminal differentiation markers androgen receptor (AR) and prostate‐specific antigen (PSA). Most adenocarcinomas are indolent and androgen‐dependent. Hormonal therapy that inhibits AR signaling produces symptomatic relief in patients with advanced and metastatic adenocarcinomas. Prostatic small cell neuroendocrine carcinoma (SCNC) is a variant form of prostate cancer (PC). In contrast to adenocarcinoma, the tumor cells of SCNC do not form glands and are negative for AR and PSA. SCNC is extremely aggressive and does not respond to hormonal therapy. The purpose of this study was to compare the important and relevant features of two most commonly used PC cell lines, LNCaP and PC3, with prostatic adenocarcinoma and SCNC.METHODSXenograft tumors of LNCaP and PC3 were prepared and compared with human prostatic adenocarcinoma and SCNC for the expression of key signaling molecules by immunohistochemistry and Western blot analysis.RESULTSLNCaP cells express AR and PSA and their growth is inhibited by androgen withdrawal, similar to human prostatic adenocarcinoma. PC3 cells do not express AR and PSA and their proliferation is independent of androgen, similar to SCNC. Adenocarcinoma cells and LNCaP cells are negative for neuroendocrine markers and stem cell‐associated marker CD44 while SCNC and PC3 cells are positive. LNCaP cells have identical cytokeratin profiles to adenocarcinoma while PC3 cells have cytokeratin profiles similar to SCNC.CONCLUSIONLNCaP cells share common features with adenocarcinoma while PC3 cells are characteristic of SCNC. Prostate 71:1668–1679, 2011. © 2011 Wiley‐Liss, Inc.

Từ khóa


Tài liệu tham khảo

Cooperberg MR, 2004, Prostate cancer 2004: Insights from national disease registries, Oncology (Williston Park), 18, 1239

Sun Y, 2009, Neuroendocrine differentiation in prostate cancer, Am J Transl Res, 1, 148

Huang J, 2007, Function and molecular mechanisms of neuroendocrine cells in prostate cancer, Anal Quant Cytol Histol, 29, 128

10.1677/ERC-07-0061

10.1016/j.eururo.2004.09.007

Bonkhoff H, 2001, Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status, Ann Oncol, 12, S141, 10.1093/annonc/12.suppl_2.S141

10.1002/pros.20434

10.1038/modpathol.3800052

10.1097/00000478-200606000-00005

10.1097/PAS.0b013e318058a96b

10.1046/j.1442-2042.2001.00347.x

10.1046/j.1464-4096.2001.00936.x

WagnerD HuangJ.Small cell carcinoma of the prostate.eMedicine from WebMD.http://emedicine.medscape.com/article/1611899‐overview.2009.

10.1016/S0022-5347(17)37427-X

10.1200/JCO.2002.12.065

10.1002/1097-0142(19870515)59:10<1803::AID-CNCR2820591019>3.0.CO;2-X

10.1016/S0022-5347(17)37390-1

Horoszewicz JS, 1980, The LNCaP cell line—A new model for studies on human prostatic carcinoma, Prog Clin Biol Res, 37, 115

Horoszewicz JS, 1983, LNCaP model of human prostatic carcinoma, Cancer Res, 43, 1809

Kaighn ME, 1979, Establishment and characterization of a human prostatic carcinoma cell line (PC‐3), Invest Urol, 17, 16

10.1002/pros.10290

10.1038/nm.2236

10.1016/S0002-9440(10)62490-X

10.1016/j.humpath.2008.07.014

10.1002/pros.21231

10.1111/j.1365-2605.2009.01030.x

10.1186/1476-4598-9-55

10.1002/pros.20928

10.2174/156652408786733667

10.1038/sj.onc.1209327

Yang Y, 1997, Differential expression of cytokeratin mRNA and protein in normal prostate, prostatic intraepithelial neoplasia, and invasive carcinoma, Am J Pathol, 150, 693

10.1046/j.1432-0436.2001.680414.x

10.1080/00365590500199855

10.1016/S0002-9440(10)63112-4

10.1023/A:1015531326689

10.1002/1097-0142(19930415)71:8<2574::AID-CNCR2820710823>3.0.CO;2-1

Pertschuk LP, 1995, Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis, Lab Invest, 73, 302

10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO;2-I

10.1517/13543784.2010.494178

10.1016/S0022-5347(05)68241-9

10.1016/S0090-4295(00)00838-4

10.1016/S0090-4295(97)00684-5

10.1038/nature08361

10.1158/0008-5472.CAN-08-4673

10.1073/pnas.0913873107

10.1126/science.1189992

Thông tin
Thông tin xuất bản

Prostate

Tập 71 Số 15

1668-1679

Thông tin tác giả